Abstract: Slide Presentations |

Value of Baseline Pulmonary Function Tests in Predicting Survival in Lung Cancer FREE TO VIEW

Robin L. Gross, MD; Hikmat N. Dagher, MD; Ziad Boujaoude, MD; Alexander Hageboutros, MD; Melvin R. Pratter, MD
Author and Funding Information

Academic, Cooper Hospital/UMDNJ, Camden, NJ


Chest. 2003;124(4_MeetingAbstracts):102S. doi:10.1378/chest.124.4_MeetingAbstracts.102S
Text Size: A A A
Published online


PURPOSE:  To determine whether pulmonary function tests (PFT) predict survival in lung cancer (LC).

METHODS:  150 patients diagnosed with LC were stratified into performance groups based on initial predicted PFTS (FEV1%, FVC%, and DLCO%). The groups for FEV1% and FVC% were: <40%, 40–59%, 60–79% and 80–100% and for DLCO% were: <50%, 50–74%, and 75%-100%. DLCO% were available for 113 patients. Survival times were compared using Kaplan-Meier (KM) product-moment curves and log-rank tests with SAS® Version 8, statistical procedure PROC LIFETEST. Multivariate analyses predicting survival were then performed stratifying across cancer staging and testing (log rank tests) for covariates: age, PFTS, ECOG score, and weight loss.

RESULTS:  Only DLCO was significantly associated with predicted survival (p=0.043) [Table

Kaplan-Meier survival based on PFTS

PFTNMedian Survival in Days, 95% CI (Range)X2 Valuep ValueFEV1 %3.470.324<4013201 (139–601)40–5937328 (202–468)60–7948376 (273–502)80–10052532 (416–808)FVC%4.4310.219<406166 (115–291)40–5936288 (201–450)60–7943400 (259–636)80–10065489 (416–640)DLCO6.290.043<5043262 (201–480)50–7443446 (334–561)75–10027882 (273–934), figure].For multivariate analysis, the KM curves across cancer stages were not equal, Χ28 = 27.67, p = <0.001. When stage was included, none of the other covariates were predictive of survival (DLCO % showed a trend towards significance, p = 0.081).CONCLUSIONS: Although baseline DLCO % initially appeared significant, multivariate analysis revealed that when cancer stage was included, no other variable added to predicted lung cancer survival.

CLINICAL IMPLICATIONS:  A larger group of patients is needed to determine whether DLCO influences survival in addition to lung cancer stage.

DISCLOSURE:  R.L. Gross, None.

Tuesday, October 28, 2003

10:30 AM - 12:00 PM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543